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The heterogeneous nature of the neuroendocrine tumors (NET) makes it challenging to ﬁnd one uniformly applicable
management protocol which is especially true for diagnosis. The discovery of the overexpression of somatostatin receptors
(SMS-R) on neuroendocrine tumor cells lead to the generalized and rapid acceptance of radiolabeled somatostatin receptor
analogs for staging and restaging of NET as well as for Peptide Receptor Radionuclide Therapy (PRRNT) using Y-90 and Lu-
177 DOTATATE/DOTATOC. In this present work we tried to look in to the eﬀect of PRRNT on the glucose metabolism assessed
by F-18 FDG PET/CT and SMS-R density assessed by Ga-68 DOTANOC PET/CT. We observed a complex relationship between
the somatostatin receptor expression and glucose metabolism with only 56% (77/138) of the lesions showing match, while
the others show mismatch between the receptor status and metabolism. The match between receptor expression and glucose
metabolism increases with the grade of NET. In grade 3 NET, there is a concurrence between the changes in glucose metabolism
and somatostatin receptor expression. PRRNT was found to be more eﬀective in lesions with higher receptor expression.
1.Introduction
Neuroendocrine tumours (NETs) are a rare but very het-
erogeneous group of neoplasms [1, 2]. NETs are generally
slow-growing tumors having a relatively good prognosis.
Although many of NETs are clinically silent, presenting
with symptoms of mass eﬀects or distant metastases [1–
3], they often lead to debilitating symptoms like diarrhea
and ﬂush, which deteriorates patients’ quality of life [4].
Surgery is the only treatment having curative intent, while
cold somatostatin analogues are primarily used for reducing
the symptoms [2, 4, 5]. However, the inhibition of secretion
ofthepeptidesresponsibleforsymptomsisoftentransientas
themediandurationofimprovementofcarcinoidsymptoms
by octreotide is known to be over 12 months [6]. Further-
more, somatostatin analogues seldom have antitumor eﬀect,
speciﬁcally if more than 10% of the liver is involved with
tumor [7–11].
Somatostatin receptor scintigraphy (SRS) is still con-
sidered as the gold standard for staging of NET. However,
recent studies have clearly shown the superiority of Ga-
68 somatostatin receptor PET/CT over SRS [12–14]. High
tumor uptake on SRS is reported to be associated with better
tumorresponsetoPRRNT[15,16]andthatisthereasonwhy
tumor uptake on SRS has been suggested as a new prognostic
factor in well-diﬀerentiated endocrine tumors [17, 18].
68Ga DOTANOC has been shown to have a very good bind-
ing aﬃnity to somatostatin receptor subtypes 2 and 3 and
higher binding aﬃn i t yt os o m a t o s t a t i nr e c e p t o rs u b t y p e5a s
compared to DOTATATE and DOTATOC [19]. On the other
hand, 18F-ﬂuorodeoxyglucose (FDG) has only limited value
in good diﬀerentiated NET and is recommended only if SRS
is negative especially in poorly diﬀerentiated NET [20, 21].
Additionally, 68Ga DOTATATE PET/CT has been shown to
be a useful novel imaging modality for NETs and was found
to be superior to 18F-FDG for imaging well-diﬀerentiated2 International Journal of Molecular Imaging
Table 1: Demographics and clinical characteristics.
Characteristics No.
Age
Mean ± SD 58.7 ± 12.2
Sex, n (%)
Male 16 (64%)
Female 9 (36%)
Pathology
GEP-NET 18
CUP 2
Carcinoid 4
Pheochromocytoma 1
Number of PRRT
11 7
up to 3 8
GEP-NET: gastroenteropancreatic neuroendocrine tumor.
NET in previous study. However, functional imaging with
both 68Ga DOTATATE and 18F-FDG has shown to address
diﬀerent biological properties of the neuroendocrine tumor
lesions in patients planned for 90YDOTATOC PET/CT
[22] and has been proposed as for comprehensive tumor
assessment in intermediate- and high-grade tumors [23]. In
our study, an intraindividual comparison was made between
the somatostatin receptor status using 68Ga DOTANOC
PET/CT and glucose metabolism using 18FF D GP E T / C T
after PRRNT.
2.MaterialsandMethods
2.1. Patient Population. Overall, 25 patients with progres-
sive, metastasized neuroendocrine tumor were included. All
the patients were imaged using FDG-PET/CT and 68Ga
DOTANOC PET/CT.
The average time interval between the two diﬀerent
PET/CTs was 3 days (mean age of 58.7 ± 12.2 years;
female to male ratio, 9:16). For precise lesion-by-lesion
comparison and to avoid any partial volume eﬀect, lesions
larger than 2cm in diameter were measured. The metastatic
lesions that were too conﬂuent or conglomerated to be
separately analyzed were excluded from the study. Detailed
demographic data are shown in Table 1.
2.2. Radiopharmaceutical Preparation
68Ga DOTANOC Labeling. To perform receptor PET/CT,
68Ga was eluted from 68Ge/68Ga generator (obtained from
Eckert and Ziegler, Berlin, Germany), and the labeling pro-
cessandassociatedqualitycontrolwereperformedaccording
to the technique mentioned in a previous publication [24,
25].
90YDO T A T A TEand177Lu DOTATATE. Both 90Y DOTATATE
and 177Lu DOTATATE were prepared in house, in a class 10
facility,understrictGMPprotocol.Theradiochemicalpurity
(checked using HPLC) of the ﬁnal preparation was always
>99%. The total amount of peptide administered in each
cycle of 90Y DOTATATE and 177Lu DOTATATE ranged from
75 to 250μg and from 160 to 500μgr e s p e c t i v e l y .
2.3. Imaging Protocols. A dual-modality PET/CT tomogra-
phy (Biograph duo; Siemens Medical Solutions) was used,
which consists of a PET system with a full-ring lutetium
oxyorthosilicate (LSO) and a CT component corresponding
to a Somatom Emotion Duo (Siemens Medical Solutions),
a 2-row spiral CT system with a maximum continuous
scan time of 100s and a maximum rotation speed of
75rpm. Water-equivalent iodine containing contrast agent
was given intravenously at 60 minutes before starting the
68Ga DOTANOC PET/CT. This dispersion is routinely used
in PET/CT without known adverse side eﬀects on the
accumulationof 68GaDOTANOC.For 18F-FDGscan,fasting
for more than 12 hours was additionally requested. In
addition, urine voiding was asked to all patients immedi-
ately before the PET/CT. The image acquisition started 60
minutes after administration of approximately 120MBq of
68Ga DOTANOC and 250MBq 18F-FDG, while the patients
were positioned head ﬁrst supine with the arms raised in
accordance with a standard CT practice and following the
EANM guidelines [26, 27]. The acquisition parameters were
kept strictly the same for pre- and post-PRRNT PET/CT
imaging.
A topogram was acquired over 1.024mm axially, and
coaxial whole-body imaging ranges were deﬁned on the
topogram from the skull to the upper thighs (7-8PET
bed positions, or 90–100cm, depending on the size of the
patient). Intravenous radioiodine contrast media of 100
milileters was injected by an automated injection pump after
checking the topogam, and contrast-enhanced CT images
were acquired during venous phase of the contrast from the
level of the skull to the thighs with a 30s delay CT in spiral
mode using a continuous acquisition at 130kVp, 115mAs,
4mm collimation, 5mm slice width, a table feed of 8mm
per rotation at 0.8s rotation time, and 2.4mm slice spacing.
For the CT image acquisition, a limited breath hold protocol
was required to the patients. Then PET emission scan was
obtained in 3-dimensional mode at each bed position for
1-2 minutes (depending upon the weight and height of
the patient) for the same coverage with the CT images,
which started in the caudocranial direction after the patients
moving automatically to the PET toward the rear of the
gantry. As a result, a total emission scan time did not exceed
24 minutes, and a total PET/CT examination took about 30
minutesincludingpatientpositioning,CT,andPETimaging.
2.4. Therapy Protocol. The legal requirements were met
in accomplishing the study (including ethical and local
radiation protection regulations). The study was performed
according to guidelines, approved by the local ethical com-
mittee at the Zentralklinik Bad Berka and in accordance
with German regulations (as published by the Federal Oﬃce
for Radiation Protection, BfS) concerning radiation safety.
Written informed consent was obtained from all patientsInternational Journal of Molecular Imaging 3
before therapy. All patients, who were enrolled in this
study, presented with progressive neuroendocrine tumors
after having exhausted all conventional therapeutic options.
Among other factors (Table 1), the degree of somatostatin
receptor expression (maximum Standardized Uptake Value
SUVmax) as determined by Ga-68 somatostatin receptor
PET/CT [28, 29], number and size of metastases, pretherapy
renal function, and hematological proﬁle was primarily
taken into consideration before estimation of the dose to be
administered, thereby individualizing the patients’ therapy.
On an average, each patient received 3.0GBq 90Y
DOTATATE and/or 7.5 GBq 177Lu DOTATATE per cycle. In
total, 17 patients were treated with only one cycle of PRRNT,
while the remaining 8 patients received upto three cycles.
2.5. Renal Protection. For kidney protection, every patient
was coinfused with 2000mL of a renoprotective amino acid
mixture of 5% Lysine HCL and 10% L-Arginine HCL in
250mL NaCl at pH 7.4 and osmolarity of 400mosmol/L.
This infusion was started 30 minutes prior to the adminis-
tration of the therapeutic dose and continued for 4 hours.
The radiopharmaceutical was coadministered over 10–15
minutes by using a second infusion pump system [30]. Each
patient was well hydrated by ensuring an intake of at least 1
litre of mineral water before therapy and 2-3 litres thereafter.
In case there was evidence of renal obstruction (physiologic
or pathological), i.v. injection of 20–40mg of furosemide
in 1.5-2 litre of deltajonin was given over 2–4 hours after
therapy.
2.6. Data Reconstruction. For attenuation correction of the
PET emission images, the CT transmission data were
used. The PET images were reconstructed iteratively using
an attenuation-weighted ordered-subsets expectation maxi-
mization algorithm with 2 iterations and 8 subsets on 128 ×
128 matrices and with a 5-minute Gaussian postreconstruc-
tion ﬁltering.
2.7. Image Evaluation and Analysis. For the analysis of
PET/CT, two diﬀerent imaging viewing systems were used
by an experienced radiologist and two experienced nuclear
medicine physicians, respectively; a Syngo viewer for the
image analysis of CT and an E. soft workstation (Siemens
Medical Solutions) for the PET/CT image assessment. At
ﬁrst, the maximum intensity projection (MIP) images were
visually examined in varying scales, and then each single
transverse slice was looked over from the skull base to
the midthighs in combination with the corresponding CT
image and the fused image slice. Each lesion showing a
focal abnormal tracer uptake was recorded by a slice number
and anatomic localization, and any lesion with intensity
greater than background which could not be explained by
physiological activity was considered to be indicative of
tumor tissue. For semiquantitative analysis of the lesions, a
region of interest (ROI) automatically drown around each
lesion maximum standardized uptake value SUVmax was
evaluated. Up to a maximum of ﬁve lesions per organ and
10 lesions in total were chosen in SUVmax o r d e rt oa v o i db i a s
of statistical counting. Changes in the size on CT (ΔCT),
SUVmax of FDG (ΔFDG), and SUVmax of 68Ga DOTANOC
(ΔSMS-R) were compared with each other.
Additionally, all the lesions were regrouped based upon
the tumor location-primary sites, liver, lymph nodes, and
bones.
2.8. Statistical Analysis. SUVmax of each lesion prior to and
after PRRNT were compared with Student’s t-test. In case
that the total number of cases was nonparametric, Wilcoxon
signed-rank test and Mann-Whitney U test were adopted.
Analysis of variance test was done to compare means of two
groups. A value of P < 0.05 was considered signiﬁcant. All
statistical analysis was carried out using MedCalc statistical
software (version 9.3.2; MedCalc, Mariakerke, Belgium).
3. Results
3.1. Analysis Based on the Uptake Pattern of Two PET/CTs. In
25 patients, a total of 133 discrete lesions were identiﬁed on
either 68Ga DOTANOC (SMS) PET/CT or 18F FDG (FDG)
PET/CT. Most lesions (n = 126, 94.7%) were positive on SMS
PET/CT, but 61.9% (n = 78) was positive on FDG PET/CT
at the same time. The remaining lesions (n = 7, 5.3%) were
only detectable by FDG PET/CT and were negative on SMS
PET/CT. The lesions were subclassiﬁed as follows: both SMS
as well as FDG positive (group A: 58.6%, n = 78), only SMS
positive (group B: n = 38, 28.6%), or FDG positive (group C:
n = 7, 5.3%). The PET/CT ﬁndings of the three groups are
shown in Figure 1.
In patients where Ki-67 was available (n = 10), 6 had
Ki-67 >2 0 %( g r a d e3N E TG 3 ) ,2h a dK i - 6 7b e t w e e n3a n d
20 (grade 2 NET G2), and 2 had Ki-67 <2% (grade 1 NET,
G1). In this subgroup of patients, FDG could pick up 67%
of the receptor-positive lesions (40/61); in G3 NET, FDG
PET could pick up 90% of the lesions (36/39). There was
a signiﬁcant correlation between the ΔFDG and ΔSMS-R.
There was signiﬁcant correlation between (32 measurable
lesions on CT also positive on FDG PET and SMS-R PET)
the ΔFDG and ΔCT (P = 0.027), between ΔFDG and ΔSMS-
R (0.007), but no signiﬁcant change between the ΔSMS-R
and ΔCT.
In group A, the SUVmax of SMS (23.0 ± 13.6 versus 17.3
± 9.4, P < 0.0001) (see Table 2 and Figure 2)a sw e l la st h e
SUVmax of FDG (9.0 ± 4.3 versus 6.6 ± 4.2, P < 0.0001)
decreased signiﬁcantly after PRRNT. The SUVmax of SMS
also decreased in group B (14.7 ± 9.1 versus 11.5 ± 8.8, P
< 0.0001), but the SUVmax of FDG in group C (12.6 ± 5.0
versus 16.9 ± 8.0, P = 0.0469) increased after PRRNT. As for
the radiotracer uptake pattern, the baseline SUVmax of SMS
ingroupAwassigniﬁcantlyhigherthanthatofgroupB(23.0
± 13.6 versus 14.7 ± 9.1, P = 0.0003). On the other hand, the
baseline SUVmax o fF D Gi ng r o u pAt e n d e dt ob el o w e rt h a n
in group C (9.0 ± 4.3 versus 12.6 ± 5.0) though it failed to
reach a statistical signiﬁcance.
3.2. Analysis Based on the Tumor Location. The lesions were
regrouped based on the location of the tumor-primary site4 International Journal of Molecular Imaging
(a) (b) (c)
Figure 1: Grouping based on the uptake of two PET/CTs. (a) Group A: a metastatic liver lesion presented both SMS (on the left) and FDG
uptake (on the right). (b) Group B: a primary tumor in the pancreas head presented SMS uptake (on the left), FDG PET/CT images on
the right showed no uptake in the primary. (c) Group C: a metastatic liver lesion presented FDG uptake (on the right) but was negative for
somatostatin receptor expression (on the left).
Table 2: Response to PRRNT: comparison of SMS-R and FDG PET/CT.
Group PET/CT Response Before PRRT After PRRT
N SUVmax N SUV†
max
Group A
SMS
CR + PR 44 27.4 ± 14.9 41 16.3 ± 9.9†
SD 24 19.1 ± 9.9 24 18.0 ± 9.5†
PD 10 12.9 ± 5.6 10 19.9 ± 7.5∗
Total 78 23.0 ± 13.6 75 17.3 ± 9.4†
FDG
CR + PR 44 9.4 ± 4.4 37 6.5 ± 4.1†
SD 24 8.2 ± 3.7 20 6.3 ± 3.2∗
PD 10 8.9 ± 5.1 7 7.1 ± 6.6
Total 78 9.0 ± 4.3 64 6.6 ± 4.2
Group B SMS
CR + PR 25 12.9 ± 9.3 15 6.7 ± 6.5†
SD 20 17.4 ± 8.9 20 16.5 ± 8.4∗
PD 3 12.0 ± 5.2 3 18.4 ± 5.8
Total 48 14.7 ± 9.1 38 11.5 ± 8.8
Group C FDG Total 7 12.6 ± 5.0 7 16.9 ± 8.0∗
†: P < 0.0001, ∗: P < 0.05.
(n = 19, 14.3%), lymph nodes metastases (n = 26, 19.5%),
liver metastases (n = 71, 53.4%), and bone metastases (n
= 17, 12.8%). The lesions were further classiﬁed according
to the receptor expression and FDG uptake; matched group
contained lesions showing somatostatin receptor expression
and FDG uptake, and the mismatched group contained
lesions which were either somatostatin receptor-positive
lesion or FDG positive. In the liver, FDG PET/CT found
additional lesions (n = 7) which did not accumulate Ga-68
DOTANOC. All the other lesions were somatostatin receptor
positive.
The pattern of SMS and FDG changes of the tumor in
response to PRRNT diﬀered by its location (see Table 3).
The receptor expression as detected by SUVmax in the
primary tumor (23.2 ± 11.0 versus 17.6 ± 8.0, P = 0.037)
and lymph nodes (21.3 ± 13.6 versus 15.3 ± 9.6, P <
0.0001) decreased signiﬁcantly after PRRNT, whereas the
corresponding FDG did not show any signiﬁcant change. In
the mismatched groups of the primary tumor and lymph
nodes, no signiﬁcant change was seen in the SMS uptake
afterthePRRNTapplication;thebaselineSUVmax werelower
than those of matched groups (primary tumor: 14.5 ± 13.5
versus 23.2 ± 11.0, P = 0.043, lymph nodes: 9.5 ± 5.1
versus 21.3 ± 13.6, P = 0.018). On the contrary, metastatic
bone lesions showed a signiﬁcant decrease of the Ga-68
DOTANOC uptake only in the mismatched group (7.5 ± 3.1
versus 5.1 ± 3.1, P = 0.007). The FDG uptake of the bone
lesions also decreased signiﬁcantly (8.6 ± 3.2 versus 3.2 ±
1.6,P =0.007).Inthematchedgroup,thebonelesionswhich
were also FDG avid did not show any signiﬁcant decrease on
receptor expression on SMS-R PET. In the liver, the changes
of each PET/CT were diﬀerent among the three subgroups.
The matched group of the liver showed signiﬁcant decreases
in both SMS uptake (26.5 ± 13.9 versus 19.6 ± 9.5, P =
0.0001) and FDG uptake (8.8 ± 4.2 versus 6.2 ± 3.6, P <
0.0001). In the mismatched group, the SUVmax of the liver
lesions showing receptor expression decreased after PRRNT
(19.0 ± 7.4 versus 14.9 ± 5.7, P = 0.0023), whereas the
SUVmax of the hepatic lesions showing only FDG uptake
increased (12.6 ± 5.0 versus 16.9 ± 8.0, P = 0.0469).International Journal of Molecular Imaging 5
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Figure 2: Relationship between SUVmax before and after PRRNT. (a) Changes of SUV on 68Ga DOTANOC (SMS) PET/CT in response to
PRRNT. The SMS uptake decreased signiﬁcantly in both group A and group B; baseline SUVmax of group A was higher than that of group
B. (b) SUV changes on 18F FDG (FDG) PET/CT in response to PRRNT. The FDG uptake decreased signiﬁcantly in group A, whereas the
uptake in group C increased. The baseline SUVmax of group C tended to be higher than that of group A. (c) The relationship between therapy
response and baseline SUVmax of 68Ga DOTANOC PET/CT. The response is positively correlated with the baseline SUVmax.
4. Discussion
It is known that NETs except benign insulinomas highly
express SMS with an incidence of 80–100%, and its density is
alsopredominantlyhigh[31].Inthisstudy,mostlesionswere
well visualized on SMS PET/CT, and more than half of the
lesions showed response by means of PRRNT. Also, higher
tumor remission rate was correlated with a high-baseline
SUVmax on SMS PET/CT. This ﬁnding is well consistent
with previous studies [16, 32], and PRRNT seems to be
quite an eﬀective therapy option for NET patients expressing
adequate densities of SMS on the tumors.
To the best of our knowledge, this study has shown
for the ﬁrst time that PRRNT seemed to have an eﬀect on
glucose metabolism of NETs showing somatostatin receptor
expression. It is well known that the changes in the FDG
correlate signiﬁcantly with tumor response [33]. Because the
ΔFDG showed signiﬁcant correlation with the ΔSMS, the
changes in ΔSMScouldbetakenasameasureoftheresponse
assessment.
This study also showed, as expected, that PRRNT is only
eﬀective in lesions showing adequate SMS expression. This
wasthereasonwhyreceptor-negativehypermetaboliclesions
progressed after PRRNT.
The main use of FDG PET in diagnosis of NETs depends
onthegradeofdiﬀerentiationand/oraggressivenessofNETs.
In our patient population with proliferation rate of more
than 20%, a very high percentage of receptor-positive lesions
were also picked up by FDG PET. Interestingly, nearly all the
measured lesions showing FDG uptake, even in patients with
high proliferation rate, showed good response to PRRNT
on CT as well as on SMS-R PET. Similar results have been
observed by Ezziddin et al. where the authors showed that
the response to PRRNT is very good even if the proliferation6 International Journal of Molecular Imaging
Table 3: Diﬀerent response patterns according to tumor location.
Location Group PET/CT Before PRRT After PRRT
N SUVmax N SUVmax
Primary sites
Mat SMS 10 23.2 ± 11.0 9 17.6 ± 8.0∗
FDG 10 9.0 ± 4.2 9 8.2 ± 4.2
Mis SMS 9 14.5 ± 13.5 5 12.9 ± 14.7
LN
Mat SMS 17 21.3 ± 13.6 17 15.3 ± 9.6†
FDG 17 9.5 ± 5.1 16 8.4 ± 5.3
Mis SMS 9 10.5 ± 5.1 5 7.5± 7.4
Liver
Mat SMS 42 26.5 ± 13.9 39 19.6 ± 9.5†
FDG 42 8.8 ± 4.2 32 6.2 ± 3.6†
Mis SMS 22 19.0 ± 7.4 21 14.9 ± 5.7∗
FDG 7 12.6 ± 5.0 7 16.9 ± 8.0∗
Bone
Mat SMS 9 9.9 ± 3.5 9 9.6 ± 4.9
FDG 9 8.6 ± 3.2 7 3.2 ± 1.6∗
Mis SMS 8 7.5 ± 3.1 7 5.1 ± 3.1∗
Abbreviations: Mat: matched, Mis: mismatched, LN: lymph nodes.
†: P < 0.0001, ∗: P < 0.05.
rate is roughly 20% [34]. This observation supports the use
of PRRNT in somatostatin receptor-positive NET. However,
there is as of yet no consensus or literature comparing
PRRNT with chemotherapy in grade 3 NET.
One of the most interesting observations in this study
was the diﬀerence in the pattern of response to PRRNT
based on the tumor localization. The response to PRRNT
was indiﬀerent to the glucose metabolism in the lymph
node metastases, liver metastases, and the primary tumor.
However, the hypermetabolic bone lesions did not show
any signiﬁcant response to PRRNT. This diﬀerence could be
related to the diﬀerent biological properties of tumor cells in
bone or bone marrow as compared to those metastasizing to
liver or lymph nodes. This observation needs to be validated
in further studies.
5. Conclusion
There is a complex relationship between the somatostatin
receptor expression and glucose metabolism with only 56%
(77/138) ofthe lesions showing match,whilethe others show
mismatch between the receptor status and metabolism. The
match between receptor expression and glucose metabolism
increases with the grade of NET. In grade 3 NET, there is a
concurrence between the changes in glucose metabolism and
somatostatin receptor expression. PRRNT is more eﬀective
in lesions with higher receptor expression.
References
[1] M. T. Barakat, K. Meeran, and S. R. Bloom, “Neuroendocrine
tumours,” Endocrine-Related Cancer, vol. 11, no. 1, pp. 1–18,
2004.
[ 2 ]I .M .M o d l i n ,K .M a r k ,I .L a t i c h ,M .N .Z i k u s o k a ,a n dM .
D. Shapiro, “Current status of gastrointestinal carcinoids,”
Gastroenterology, vol. 128, no. 6, pp. 1717–1751, 2005.
[3] G. A. Kaltsas, G. Besser, and A. B. Grossman, “The diag-
nosis and medical management of advanced neuroendocrine
tumors,” Endocrine Reviews, vol. 25, no. 3, pp. 458–511, 2004.
[4] K. Oberg and B. Eriksson, “Medical treatment of neuroen-
docrine gut and pancretic tumors,” Acta Oncologica, vol. 28,
no. 3, pp. 425–431, 1989.
[5] D. J. Kwekkeboom, E. P. Krenning, R. Lebtahi et al., “ENETS
consensus guidelines for the standards of care in neuroen-
docrine tumors: peptide receptor radionuclide therapy with
radiolabeled somatostatin analogs,” Neuroendocrinology, vol.
90, no. 2, pp. 220–226, 2009.
[6] L. K. Kvols, C. Moertel, and M. J. O’Connell, “Treatment of
themalignantcarcinoidsyndrome.Evaluationofalong-acting
somatostatin analogue,” The New England Journal of Medicine,
vol. 315, no. 11, pp. 663–666, 1986.
[7] A. Rinke, H. H. Muller, C. Schade-Brittinger et al., “Placebo-
controlled, double-blind, prospective, randomized study on
the eﬀect of octreotide LAR in the control of tumor growth
in patients with metastatic neuroendocrine midgut tumors:
a report from the PROMID study group,” Journal of Clinical
Oncology, vol. 27, no. 28, pp. 4656–4663, 2009.
[8] S. Faiss, U. Pape, M Bohmig et al., “Prospective, randomized,
multicenter trial on the antiproliferative eﬀe c to fl a n r e o t i d e ,
inteferon alfa, and their combination for therapy of metastatic
neuroendocrine gastroenteropancreatic tumors—the interna-
tional lanreotide and interferon alfa study group,” Journal of
Clinical Oncology, vol. 21, no. 14, pp. 2689–2696, 2003.
[9] E. T. Janson and K. Oberg, “Long-term management of the
carcinoid syndrome. Treatment with octreotide alone and in
combination with α-interferon,” Acta Oncologica, vol. 32, no.
2, pp. 225–229, 1993.
[10] F. Panzuto, M. Di Fonzo, E. Iannicelli et al., “Long-term
clinical outcome of somatostatin analogues for treatment of
progressive, metastatic, well-diﬀerentiated entero-pancreatic
endocrine carcinoma,” Annals of Oncology, vol. 17, no. 3, pp.
461–466, 2006.
[11] H. Shojamanesh, F. Gibril, L. Adeline et al., “Prospective study
of the antitumor eﬃcacy of long-term octreotide treatment in
patients with progressive metastatic gastrinoma,” Cancer, vol.
94, no. 2, pp. 331–343, 2002.International Journal of Molecular Imaging 7
[12] I. Buchmann, M. Henze, S. Engelbrecht et al., “Comparison
of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan)
SPECT in patients with neuroendocrine tumours,” European
JournalofNuclearMedicineandMolecularImaging,vol.34,no.
10, pp. 1617–1626, 2007.
[13] M. Hofmann, H. Maecke, A. Borner et al., “Biokinetics
and imaging with the somatostatin receptor PET radioligand
68Ga-DOTATOC: preliminary data,” European Journal of
Nuclear Medicine, vol. 28, no. 12, pp. 1751–1757, 2001.
[ 1 4 ]J .K o w a l s k i ,M .H e n z e ,J .S c h u h m a c h e r ,R .M .H e l m u t ,H .
Michael, and H. Uwe, “Evaluation of positiron emission
tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-
Octreotide in comparison to [111In]-DTPAOC SPECT. First
results in patients with neuroendocrine tumors,” Molecular
Imaging & Biology, vol. 5, no. 1, pp. 42–48, 2003.
[15] D. J. Kwekkeboom, W. Bakker, B. L. Kam et al., “Treatment
of patients with gastro-entero-pancreatic (GEP) tumours
with the novel radiolabelled somatostatin analogue [177Lu-
DOTA0,Tyr3]octreotate,” European Journal of Nuclear
Medicine and Molecular Imaging, vol. 30, no. 3, pp. 417–422,
2003.
[16] D. J. Kwekkeboom, W. W. de Herder, B. L. Kam et al.,
“Treatment with the radiolabled somatostatin analog [177Lu-
DOTAo,Tyr3] octreotate: toxicity, eﬃcacy and survival,” Jour-
nal of Clinical Oncology, vol. 26, no. 13, pp. 2124–2130, 2008.
[17] A. R. Haug, C. J. Auernhammer, G. P. Schmidt et al., “68Ga-
DOTATATE PET/CT for the early prediction of response
to somatostatin receptor-mediated radionuclide therapy in
patients with well-diﬀerentiated neuroendocrine tumors,”
Journal of Nuclear Medicine, vol. 51, no. 9, pp. 1349–1356,
2010.
[18] A. Asnacios, F. Courbon, P. Rochaix et al., “Indium-111-
pentetreotide scintigraphy and somatostatin receptor subtype
2 expression: new prognostic factors for malignant well-
diﬀerentiated endocrine tumors,” Journal of Clinical Oncology,
vol. 26, no. 6, pp. 963–970, 2008.
[19] D. Wild, J. S. Schmitt, M. Ginj et al., “DOTA-NOC, a high-
aﬃnity ligand of somatostatin receptor subtypes 2, 3 and 5
for labelling with various radiometals,” European Journal of
Nuclear Medicine and Molecular Imaging, vol. 30, no. 10, pp.
1338–1347, 2003.
[20] S. Adams, R. Baum, T. Rink, and K. H. Usadel, “Limited
value of ﬂuorine-18 ﬂuorodeoxyglucose positron emission
tomography for the imaging of neuroendocrine tumours,”
European Journal of Nuclear Medicine, vol. 25, no. 1, pp. 79–
83, 1998.
[21] C. Pasquali, D. Rubello, C. Sperti et al., “Neuroendocrine
tumorimaging:can 18F-ﬂuorodeoxyglucosepositronemission
tomographydetecttumorswithpoorprognosisandaggressive
behavior?” World Journal of Surgery, vol. 22, no. 6, pp. 588–
592, 1998.
[22] S. Koukouraki, L. G. Strauss, V. Georgoulias, M. Eisenhut, U.
Haberkorn, and A. Dimitrakopoulou-Strauss, “Comparison
of the pharmacokinetics of 68Ga-DOTATOC and [ 18F]FDG
in patients with metastatic neuroendocrine tumours sched-
uled for 90Y-DOTATOC therapy,” European Journal of Nuclear
Medicine and Molecular Imaging, vol. 33, no. 10, pp. 1115–
1122, 2006.
[23] I. Kayani, J. B. Bomanji, A. Groves et al., “Functional imaging
of neuroendocrine tumors with combined PET/CT using
68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-
FDG,” Cancer, vol. 112, no. 11, pp. 2447–2455, 2008.
[24] K. P. Zhernosekov, D. V. Filosofov, R. P. Baum et al., “Pro-
cessing of generator-produced 68Ga for medical application,”
Journal of Nuclear Medicine, vol. 48, no. 10, pp. 1741–1748,
2007.
[25] G. J. Meyer, J. Schuhmacher, W. H. Knapp, and M. Hofmann,
“68Ga-labelled DOTA-derivatised peptide ligands,” European
JournalofNuclearMedicineandMolecularImaging,vol.31,no.
8, pp. 1097–1104, 2004.
[26] I. Virgolini, V. Ambrosini, J. B. Bomanji et al., “Procedure
guidelines for PET/CT tumour imaging with 68Ga-DOTA-
conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC,
68Ga-DOTA-TATE,” European Journal of Nuclear Medicine
and Molecular Imaging, vol. 37, no. 10, pp. 2004–2010, 2010.
[27] R. Boellaard, M. J. O’Doherty, W. A. Weber et al., “FDG PET
and PET/CT: EANM procedure guidelines for tumour PET
imaging: version 1.0,” European Journal of Nuclear Medicine
and Molecular Imaging, vol. 37, no. 1, pp. 181–200, 2010.
[28] R. P. Baum, V. Prasad, M. Hommann, and D. Horsch, “Recep-
tor PET/CT imaging of neuroendocrine tumors,” Recent
Results in Cancer Research. Fortschritte der Krebsforschung, vol.
170, pp. 225–242, 2008.
[29] V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S.
Fanti, and R. P. Baum, “Detection of unknown primary
neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-
NOC receptor PET/CT,” European Journal of Nuclear Medicine
and Molecular Imaging, vol. 37, no. 1, pp. 67–77, 2010.
[30] A. Rimpler, I. Barth, R. B. Baum, S. Senftleben, and L.
Geworski, “β radiation exposure of staﬀ during and after
therapies with 90Y-labelled substances,” Radiation Protection
Dosimetry, vol. 131, no. 1, pp. 73–79, 2008.
[31] J. C. Reubi, L. K. Kvols, B. Waser et al., “Detection of
somatostatin receptors in surgical and percutaneous needle
biopsy samples of carcinoids and islet cell carcinomas,”Cancer
Research, vol. 50, no. 18, pp. 5969–5977, 1990.
[32] D. J. Kwekkeboom, J. J. Teunissen, W. H. Bakker et al., “Radi-
olobeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate
in patients with endocrine gastroenteropancreatic tumors,”
Journal of Clinical Oncology, vol. 23, no. 12, pp. 2754–2762,
2005.
[33] R. P. Baum and V. Prasad, “Monitoring treatment,” in Clinical
Nuclear Medicine,G .J .R .C o o k ,M .N .M a i s e y ,K .E .B r i t t o n ,
and V. Chengazi, Eds., pp. 57–78, Hodder Arnold, London,
UK, 4th edition, 2006.
[34] S. Ezziddin, M. Opitz, M. Attassi et al., “Impact of the
Ki-67 proliferation index on response to peptide receptor
radionuclide therapy,” European Journal of Nuclear Medicine
and Molecular Imaging, vol. 38, no. 3, pp. 459–466, 2010.